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Background: The application of precision medicine in oncology requires in-depth characterisation of a patient’s
tumours and the dynamics of their responses to treatment.
Patients and methods: We used next-generation sequencing of circulating cell-free DNA (cfDNA) to monitor the
response of a KIT p.L576P-mutant metastatic vaginal mucosal melanoma to sequential targeted, immuno- and
chemotherapy.
Results: Despite a KIT mutation, the response to imatinib was mixed. Unfortunately, tumours were not accessible for mo-
lecular analysis. To study the mechanism underlying the mixed clinical response, we carried out whole-exome sequencing
and targeted longitudinal analysis of cfDNA. This revealed two tumour subclones; one with a KIT mutation that responded
to imatinib and a second KIT-wild-type subclone that did not respond to imatinib. Notably, the subclones also responded
differently to immunotherapy. However, both subclones responded to carboplatin/paclitaxel, and although the KIT-wild-type
subclone progressed after chemotherapy, it responded to subsequent re-administration of paclitaxel.
Conclusion: We show that cfDNA can reveal tumour evolution and subclonal responses to therapy even when biopsies
are not available.
Key words: vaginal mucosal melanoma, circulating cell-free DNA, next-generation sequencing, clonal response to
therapy
introduction
Mucosal melanoma is a rare disease that accounts for ∼1.1% of
all melanomas and has an incidence of 2.3 per million person-
years [1]. It is characterised by a low mutation burden and a
prevalence of chromosomal and copy number aberrations [2, 3].
BRAF mutations are rare, but ampliﬁcation or mutations in the
receptor tyrosine kinase KIT occur in ∼40% of cases [3, 4]. KIT
aberrations are also frequent in acral melanomas and cutaneous
melanomas arising over chronically sun-damaged skin, prompt-
ing clinical trials of KIT inhibitors in KIT-mutant melanoma
[4, 5]. A phase II study of 25 patients reported objective
responses to the KIT inhibitor imatinib in 54% (7/13) of KIT-
mutant patients, versus 0% in patients with KIT ampliﬁcations
[6]. The most common sites of mucosal melanoma are sinona-
sal, anorectal and urogenital, and while primary vaginal
melanomas are rare, possibly because melanocytes are only
found in the vaginal mucosa of ∼3% of women, the outcome for
these patients is particularly poor and clinical management
guidelines have not yet been agreed [1, 7].
Precision medicine offers an opportunity to improve patient
care, particularly in rare cancers where clinical trials are difﬁ-
cult due to small patient populations. The cornerstone of pre-
cision medicine is next-generation sequencing (NGS), which
can provide unbiased identiﬁcation of actionable mutations.
These approaches are increasingly used in clinical settings, but
require access to high-quality tumour samples and knowledge
of the underlying genomic landscape of the tumour to be fully
effective. However, due to its rarity and proclivity for meta-
stasising to poorly accessible visceral sites, our knowledge of
the genomics of vaginal mucosal melanoma is still limited. A
possible way around these limitations is to analyse the DNA
released by the tumour into the patient’s blood. Critically, cir-
culating cell-free DNA (cfDNA) can accurately reﬂect the
genomic landscapes of solid tumours and has been used to
follow patient responses to therapy [8, 9], but to date these
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studies have largely been limited to analysing mutations identi-
ﬁed from previous sequencing campaigns, tumour biopsies,
autopsy material or accessible metastatic sites [9–11], none of
which are typically available in vaginal mucosal melanoma.
We describe a patient with KIT-mutant vaginal mucosal mel-
anoma who received sequential targeted, immuno- and chemo-
therapy. Metastatic lesions were inaccessible for molecular
analysis, so we carried out whole-exome sequencing (WES) and
targeted longitudinal analysis of cfDNA to monitor the patient’s
response to therapy. We found that the patient presented
two tumour subclones that responded differently to treatment.
Moreover, the cfDNA analysis predicted response to therapy
and progression several weeks before these were conﬁrmed by
radiological scans. Our study shows that the dynamic analysis of
cfDNA can reveal tumour heterogeneity, clonal responses to
treatment and tumour evolution even when metastatic lesions
are inaccessible, illustrating the enormous potential of this ap-
proach in supporting precision medicine procedures.
patients andmethods
DNA isolation
Ethical approval was granted by the Manchester Cancer Research Centre
(MCRC) Biobank Access Committee (Protocol number 13RIMA01). The
patient provided written informed consent. Extraction and quantiﬁcation of
cfDNA was carried out as described previously [12]. Germline DNA was
extracted from the remaining whole blood fraction following centrifugation
using QIAamp DNA Blood Mini kits (Qiagen, Valencia, CA) by the manu-
facturer’s instructions. DNA from formalin-ﬁxed, parafﬁn-embedded
(FFPE) material was isolated using GeneRead DNA FFPE kits (Qiagen) by
the manufacturer’s instructions.
targeted re-sequencing
A DNA fragment spanning KIT p.L576 (1 ng input cfDNA) or a multiplexed
panel of 15 loci (2 ng input cfDNA) were PCR ampliﬁed using GeneRead
DNAseq Panel PCR Kits V2 (Qiagen). Primer sequences and amplicon char-
acteristics are summarised in supplementary Table S1, available at Annals of
Oncology online. The multiplex PCR panel was designed using MPprimer
[13], but speciﬁc primers could not be generated for UGT2B11 p.D458H.
PCR reactions were carried out in a total volume of 40 or 50 μl (for single
locus or multiplex ampliﬁcations, respectively) and contained 3 or 3.75 U of
GeneRead HotStarTaq DNA polymerase (Qiagen) and a ﬁnal concentration
of 0.5 μM of each primer. The PCR programme included 1 cycle at 95°C for
15 min, 35 or 30 cycles of 95°C for 15 s, 55°C for 30 s and 60°C for 30 s and
a ﬁnal elongation step at 72°C for 10 min. PCR products were gel-puriﬁed
using QIAquick Gel Extraction kits (Qiagen) and 50 or 200 ng used for
library preparation. Sequencing libraries were prepared using the NEBNext
Ultra DNA Library Prep Kit and NEBNext Multiplex Oligos for Illumina
(New England Biolabs, Ipswich, MA) according to the manufacturer’s
instructions and processed on an Illumina MiSeq (Illumina, San Diego, CA).
Raw reads were ﬁrst processed using Cutadapt (v. 1.8.3) to clip Illumina
adapters and PCR primers. Trimmomatic (v. 0.32) was used to ﬁlter out low
quality reads. The quality control processed fastq were aligned to the human
genome (GRCh37) using BWA (v. 0.7.7) and the GATK (v. 3.3) framework
was used for realignment around InDels. Samtools (v. 0.1.19) was used to
convert the ﬁnal BAMs (binary form of alignment output) to pileup format.
Variants identiﬁed from pileup ﬁles using VarScan (v. 2.3.6) were then anno-
tated using Variant Effect Predictor (VEP) (v. 73).
whole-exome sequencing
Sequencing libraries were generated from 10 or 25 ng cfDNA, or 200 ng
sheared germline DNA in Accel-NGS 2S DNA Library Kits for the Illumina
Platform (Swift Biosciences, Ann Arbor, MI) by the manufacturer’s instruc-
tions with the following modiﬁcations. Library ampliﬁcation and indexing was
carried out with KAPA HiFi HotStart PCR Kits (Kapa Biosystems,
Wilmington, MA) and NEBNext Index Primers for Illumina (New England
Biolabs). PCR-ampliﬁed libraries were quantiﬁed by Qubit 2.0 Fluorometer
(Life Technologies, Carlsbad, CA) and 333 ng of each used for whole exome
capture on SureSelectXT Reagent Kits (Agilent, Santa Clara, CA) by the man-
ufacturer’s instructions. Captured libraries were ampliﬁed using KAPA HiFi
HotStart PCR Kits and PE1 (50-AATGATACGGCGACCACCGAGATCT-30)/
PE2 (50-CAAGCAGAAGACGGCATACGAGAT-30) primer. Libraries were
processed on an Illumina NextSeq (Illumina).
Raw fastq ﬁles were processed to remove low-quality reads using
Trimmomatic (v. 0.32) and the resultant fastq ﬁles aligned to the human
genome (GRCh37) using BWA aligner (v. 0.7.7). Picard (v. 1.107) was used
to mark PCR duplicates in the BAM ﬁles and subsequently, the GATK
framework (v. 3.3) and the InDels from 1000 Genome consortia (phase I)
and SNPs from dbSNP (release 38) were used to perform realignment and
mapping quality score recalibration. Somatic single-nucleotide variations
(SNVs) and InDels were identiﬁed by comparison to the germline DNA
pileup ﬁle using VarScan software (v. 2.3.6). Finally, the mutations were
annotated for genetic context using VEP (v. 73).
copy number analysis
For WES-based copy number analysis, per base read-depth coverage was gen-
erated from ﬁnal BAM ﬁles using bedtools (v. 2.20.1) and ADTEX (v. 2.0) was
used to identify regions with copy number alterations by comparing tumor
and normal coverage ﬁles. Copy number calls were plotted in an exome-wide
composite graph using R (v. 3.1.3). For droplet digital PCR, 25 ng DNA iso-
lated from FFPE material or reference germline DNA were subjected to
HIndIII/EcoRI (10 U each/reaction) double-restriction enzyme digestion in a
total volume of 10 μl for 1 h at 37°C. After adding 90 μl of water, 8.8 μl of
the reaction was combined with 11 μl ddPCR Supermix for Probes (No
dUTP) (Bio-rad, Hercules, CA), 1.1 μl of KIT (Hs02812715_cn) or NLGN4X
(Hs02584007_cn)-speciﬁc probe and 1.1 μl of TERT TaqMan Copy Number
Reference Assay (all Thermo Fisher Scientiﬁc, Waltham, MA). Droplets were
generated and analysed using the QX200 AutoDG Droplet Digital PCR system
according to the manufacturer’s instructions (Bio-rad). For cfDNA analysis, 2
ng cfDNA or reference germline DNA (sheared to ∼150 bp using an S2 series
focused-ultrasonicator, Covaris, Woburn, MA) was used directly for analysis.
All reactions were carried out in triplicate and repeated at least twice.
three-dimensional tumour measurements
The volumes of all metastatic lesions were estimated based on computed
tomography (CT) image measurements using the formula for the volume
calculation of ellipsoid shapes V = 4/3 × π(A/2)(B/2)(C/2), where A and B
were the perpendicular diameters at maximum area representation on the
axial plane and C was calculated from axial slices by multiplying the slice
thickness (3 mm) by the number of slices between the cephalic and caudal
tip of the metastasis.
results
The patient presented in her mid-40s with a vaginal vestibule
mass, which a biopsy revealed to be a 14 mm thick, ulcerated
melanoma with 29 mitoses/mm2. CT revealed an advanced
tumour invading the rectum, so radical vaginovulvectomy,
abdominoperineal resection and abdominal hysterectomy with
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bilateral salpingo-oophorectomy were carried out. Liver metas-
tases developed 5 months later and following disease progres-
sion on dacarbazine (1000 mg/m2, two cycles), given that a KIT
p.L576P mutation was present in the primary tumour biopsy,
imatinib was administered (400 mg/day). The response to imati-
nib was mixed, with tumour reduction in an inguinal lymph
node, but growth of a liver lesion and a new deposit appearing
in the peritoneum, so imatinib was discontinued (Figure 1A–C;
supplementary Figure S1, available at Annals of Oncology
online).
Due to disease progression in the liver, the patient received ipi-
limumab (3 mg/kg), but discontinued after only two cycles
because of disease progression and grade 3 toxicity (Figure 1A–C,
supplementary Figure S1, available at Annals of Oncology
online). The patient also progressed on pembrolizumab (2 mg/
kg, ﬁve cycles) with widespread intra-abdominal disease, but she
responded to paclitaxel (175 mg/m2) and carboplatin (AUC 6),
with a 60% reduction in target lesions size (by RECIST 1.1) after
two cycles and further reduction in existing lesions and no new
lesions on completion of this course of treatment (week 67;
Figure 1B and C). The response to paclitaxel/carboplatin was ac-
companied by a reduction in lactate dehydrogenase from over
ﬁve times the upper limit of normal to within the normal range.
However, a scan at week 80 revealed progression with growth of
the tumours in the liver and peritoneum, but not the nodal sites
(Figure 1A–C, supplementary Figure S1, available at Annals of
Oncology online), so paclitaxel (175 mg/m2) was reinitiated and
led to a clear improvement in clinical symptoms.
We were intrigued by the patient’s mixed response to imati-
nib, particularly because targeted sequencing of the cfDNA
revealed complete suppression of KIT p.L576P in the presence
of imatinib and then rebounding when imatinib was withdrawn
(Figure 1D). Unfortunately, as is common with vaginal mucosal
melanoma, the metastatic lesions were inaccessible in this
patient and only FFPE samples from the primary tumour were
available for analysis, so we carried out WES of cfDNA isolated
at week 37 and compared it with DNA isolated from white
blood cells. We analysed 10 and 25 ng of cfDNA to provide
technical replicates, and this revealed 15 reproducible somatic
SNVs (Figure 2A). We developed a custom multiplexed targeted
sequencing panel to monitor these SNVs in the patient’s cfDNA
(supplementary Table S1, available at Annals of Oncology
online) and conﬁrmed excellent correlation between the variant
allele frequencies (VAF) determined by this panel and WES
(R2 = 0.9512, Figure 2B). Note that UGT2B11 p.D458H failed to
amplify, so could not be assessed. We also observed excellent
correlation between longitudinal KIT p.L576P analyses using
the targeted single locus analysis and the multiplex panel (sup-
plementary Figure S2, available at Annals of Oncology online).
The results were reproducible in three independent week 37
cfDNA replicates, with a maximum VAF standard deviation of
1.62%, and germline readings not exceeding 0.27%, so a robust
detection cut-off of 1% was set for subsequent analyses (supple-
mentary Figure S3, available at Annals of Oncology online).
Intriguingly, longitudinal analysis of the patient’s cfDNA
revealed that the SNVs separated into two clusters with distinct
responses to treatment (Figure 2C). Cluster 1 included eight
SNVs and emerged during dacarbazine, disappeared under
imatinib, returned on ipilimumab and pemprolizumab, and
reduced again on carboplatin/paclitaxel (Figure 2C). Note that
KIT p.L576P followed the same pattern as cluster 1, but at ap-
proximately ﬁvefold higher VAF (Figure 2C). We carried out
copy number analysis of the WES data and observed extensive
regions of chromosomal loss and gain including focal ampliﬁca-
tion of KIT (Figure 2D). We conﬁrmed the KIT ampliﬁcation by
droplet digital PCR (supplementary Figure S4, available at
Annals of Oncology online) and reasoned that KIT p.L576P
belonged to cluster 1, but had increased VAF due to gene ampli-
ﬁcation. Cluster 2 consisted of six SNVs, including SF3B1
p.R625H and also emerged under dacarbazine, but in contrast
to cluster 1, it increased during imatinib (Figure 2C). During
ipilimumab cluster 2 decreased, but contrary to cluster 1, it
increased on pembrolizumab, before falling away during carbo-
platin/paclitaxel (Figure 2C). Only cluster 2 SNVs re-emerged
after completion of the course of carboplatin/paclitaxel, predict-
ing relapse of this clone 3 weeks before a CT conﬁrmed the
growth of tumours in the liver and peritoneum (Figures 1B and
C and 2C and supplementary Figure S1, available at Annals of
Oncology online). Note also that cluster 2 responded to pacli-
taxel re-administration and the commensurate improvement in
clinical symptoms.
Thus, our longitudinal analysis revealed that the patient had
two distinct tumour subclones that responded differently to
treatment and the patterns of tumour and cfDNA responses
suggest that cluster 1 is associated with the nodal disease,
whereas cluster 2 is associated with the liver and peritoneal
disease. To investigate the source of subclone heterogeneity in
this patient, we carried out targeted sequencing of the diagnostic
biopsy that was used to identify the KIT p.L576P mutation. We
conﬁrmed that all 14 assessable SNVs were present in this
primary tumour sample (Figure 3A), but when we examined a
second FFPE specimen taken during the patient’s subsequent
radical surgery, we only observed cluster 2 SNVs (Figure 3A),
demonstrating that the second biopsy was dominated by the
cluster 2 subclone.
Consistent with the ampliﬁcation of mutant KIT in the
cluster 1 subclone, targeted sequencing revealed a high KIT p.
L576P VAF in the clonally mixed diagnostic biopsy, but not the
cluster 2-dominated surgery biopsy (Figure 3A). Unexpectedly,
we also observed a high NLGN4X p.T134S VAF in the mixed-
clone diagnostic biopsy (Figure 3A), but NLGN4X was not amp-
liﬁed during the cfDNA analysis (Figure 2D and supplementary
Figure S4, available at Annals of Oncology online), so we carried
out copy number analysis by droplet digital PCR. We conﬁrmed
the KIT ampliﬁcation in the diagnostic biopsy, but not the
surgery biopsy (Figure 3B) and while NLGN4X was not ampli-
ﬁed in the diagnostic biopsy, we observed copy number loss in
the surgery biopsy (Figure 3B). We conclude that the apparent
high NLGN4X p.T134S VAF in the clonally mixed diagnostic
biopsy is accounted for by the loss of a wild-type NLGN4X allele
in the cluster 2 subclone.
discussion
We report a case of KIT-mutant vaginal mucosal melanoma
with a mixed response to imatinib that caused the drug to be
withdrawn after only 8 weeks. Longitudinal cfDNA analysis
revealed complete loss of KIT p.L576P under imatinib with a
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rapid return when imatinib was discontinued. Strikingly, this
response coincided with shrinkage of a metastatic inguinal
nodal lesion under imatinib and progression at this site when
imatinib was discontinued, whereas the metastatic liver disease
progressed through imatinib. It has been reported that cfDNA
can reveal complex responses to therapy, but most previous
studies have relied on targeted sequencing panels derived from
biopsy or autopsy material, or knowledge of genomic land-
scapes of the tumours obtained from large sequencing cam-
paigns [8, 9, 11, 14]. However, little is known about the
mutational landscape of vaginal melanoma and, as is common
in routine management of cancer patients, tumour biopsies
from individual metastatic deposits were not available and
primary tumour biopsies were preserved as FFPE specimens.
Moreover, as the patient is still under treatment, autopsy biop-
sies were unavailable.
To overcome these challenges, we used WES of cfDNA to in-
vestigate the mechanism underlying the patient’s mixed response
to therapy and to search for potential therapeutic targets. Our
analysis revealed that the patient presented with two tumour
subclones that displayed distinct responses to targeted (imatinib)
and immuno (pembrolizumab)-therapies. Importantly, targeted
sequencing of the diagnostic biopsy did not reveal the presence of
two subclones, and sequencing of the surgery biopsy revealed
only one of the subclones. This illustrates the limitations in analys-
ing solid tumour biopsies, as single biopsies cannot reveal subclo-
nal mixtures in a tumour unless single-cell analysis is carried out.
Moreover, single tumour biopsies may provide incomplete genetic
information if there is subclonal dominance within the sampled
region and, as in our case, this could result in actionable muta-
tions being missed. Similarly, single cfDNA samples cannot reveal
subclonal populations or their responses to therapy. However, the
A
B
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Figure 1. Levels of KIT p.L576P in the circulating cell-free DNA (cfDNA) respond to imatinib. (A) Overview of patient’s treatment history, including informa-
tion on initial diagnosis (35 weeks before follow-up) and surgery. Organ denominations indicate sites of metastatic disease as detected by computed tomog-
raphy (CT) scans. Red font, progression; green font, response; DTIC, dacarbazine; Ipi., ipilimumab; Pembro., pembrolizumab. (B) Routine CT-generated
images of the liver (top panels) and inguinal lymph node (bottom panels) at the indicated times. DTIC, dacarbazine; carbo./pacli., carboplatin/paclitaxel. (C)
RECIST 1.1 measurements of a segment II liver metastasis and the inguinal (ing.) lymph node lesion during treatment with dacarbazine (D), imatinib (Im), ipi-
limumab (Ip), pembrolizumab (Pem) and carboplatin/paclitaxel (C/P) corresponding to (B). (D) Prospective quantiﬁcation of KIT p.L576P VAF in cfDNA up
to week 37. DTIC, dacarbazine.
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combination of WES and targeted longitudinal monitoring of the
cfDNA revealed not only the presence of the individual subclones,
but also their genetic constitution and distinct responses to
therapy. Critically, we achieved this level of insight even though
the patient’s metastatic lesions were inaccessible.
Our data are consistent with the mixed response to imatinib
and indicate that it was effective, albeit in a single clone. We
were not able to determine the relationship between the
subclones and it is curious that they appeared not to share any
common mutations. One possibility is that they were related
through truncal drivers such as copy number gains and losses,
fusion genes or epigenetic modiﬁcations that are characteristic
of mucosal melanoma, but not revealed by longitudinal targeted
sequencing. Alternatively, the clones may not have been related,
but we conﬁrmed that both were present in at least part of the
primary tumour, suggesting that they emerged from the same
A B
C
D
Figure 2. Circulating cell-free DNA (cfDNA) reveals two tumour subclones with distinct responses to therapy. (A) Venn diagram showing single-nucleotide
variations identiﬁed by whole-exome sequencing (WES) of cfDNA collected at week 37. The diagram shows the mutations detected in the 25 or 10 ng input
samples, with common mutations in the intersection. KIT p.L576P is highlighted in red to conﬁrm its identiﬁcation in both WES runs. (B) Correlation of
variant allele frequencies (VAFs) detected by WES or targeted sequencing in the week 37 cfDNA sample. WES-based VAFs represent average values of the two
input DNA amounts. (C) VAFs of 14 mutations (see legend within the ﬁgure) in cfDNA from samples collected at the indicated times. VAFs of mutations in
clusters 1 and 2 are connected by black and blue lines, respectively, and the treatments administered are indicated above the graph. DTIC, dacarbazine; Ipi., ipi-
limumab. (D) Copy number variation by chromosome (chr.) based on WES from the two different input cfDNA amounts isolated at week 37 of follow-up.
Grey and red dots indicate allele loss (both and one, respectively), green dots indicate normal copy number state and blue and light blue dots indicate copy
number gains (three and four or more copies, respectively).
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site. Critically, irrespective of their origins, we identiﬁed poten-
tial therapeutic targets for both clones in the cfDNA; imatinib
was effective against the cluster 1 clone, and a mutation in
SF3B1, a component of the spliceosome and a validated drug
target [15], was discovered in the cluster 2 clone.
In conclusion, we show that WES and longitudinal, targeted
analysis of cfDNA can overcome the need for biopsies to reveal
subclonal responses to treatment. Despite the clinical diagnosis
of disease progression, we showed that imatinib controlled one
subclone, and its withdrawal allowed this subclone to re-emerge.
This suggests that imatinib would be a valid option for combin-
ation therapy for this patient, although targeted options for
cluster 2 are not yet in the clinic and potential compound tox-
icity may limit the use of unproven combination therapies in
patients. Our analysis also provided an early indication that
both subclones responded to chemotherapy and it predicted
relapse of one of the subclones before it was revealed by a radio-
logical scan. The key to precision medicine is a better under-
standing of tumour complexity and the dynamics of response to
treatment and we show that this can be provided by the analyses
we carried out. Moreover, the approach is convenient for the
patient, simple to implement and relatively inexpensive.
Although alternative treatment options were not available for
our patient, we provide an important proof of principle of how
in-depth cfDNA analysis can improve patient care through im-
plementation of personalised medicine.
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